A new medication, named Ocrelizumab, released by Roche may prove to become an innovative cure against multiple sclerosis (MS), according to reviews published in American medical journals. The substance has already been examined in individual late stage tests and has confirmed some of its beneficial properties in bone affections.
Since researchers were not able to determine the real cause of MS, the treatments applied until recently have been restricted. For many years, a drug called Rebif has been considered the most efficient treatment against multiple sclerosis. Nevertheless, even if Rebif has been quite good for less severe cases of MS, it was shown to be mostly useless against advanced problems caused by multiple sclerosis, which affects approximately 15% of MS sufferers.
Ocrelizumab was confirmed to be extremely efficient in both dealing with the illness and reducing its development. For their tests, doctors followed over 700 patients having less common, but very serious, cases of MS. Ocrelizumab has proved its efficiency at stopping a relapse of multiple sclerosis symptoms. The tests indicate that this medication provides a 45% and 46% decrease in relapse cases (annualized). MS sufferers had a 24% reduction of illness development over 3 months, and a 25 % decrease over 6 months.
In two of these studies, 1,650 people with recurring MS were followed over a longer period of time, and Ocrelizumab turned out to be more efficient at curing multiple sclerosis than current treatments.
Therapy with ocrelizumab considerably decreased the annualized relapse over a one-year interval in comparison to interferon 1a, the main endpoint in these studies. Ocrelizumab also considerably decreased the development of healthcare impairment in contrast to interferon 1a, as calculated based on Extended Disability Range. Furthermore, treatments with ocrelizumab produced an important decrease in the percentage of brain lesions (areas of illness activity) in comparison to interferon 1a, according to MRI evaluation.
Overall, the occurrence of negative effects associated with this drug was just like interferon 1a in previous tests, the most typical side effects being moderate infusion responses. The incidence of serious negative symptoms linked to ocrelizumab, such as severe infections, was almost identical to that of interferon 1a.
Ocrelizumab revealed amazing developments over a standard medication strategy across healthcare and imaging results in both medical tests. Ocrelizumab is a prospective treatment able to make an important difference for individuals with multiple sclerosis, a serious and devastating chronic illness. Based on such powerful results, experts plan to send their information for evaluation to both US and EU regulating authorities during the first semester of 2016.
Ongoing studies of this drug are conducted on extended samples of MS patients and specific information will be provided at future healthcare congresses. Results from stage 3 research of ocrelizumab in individuals with progressive multiple sclerosis, a different type of MS, will be released later this month. At this point in time, results are very encouraging for both patients and doctors who are looking for more efficient treatments against chronic and debilitating diseases.